|
Originally published In Press as doi:10.1074/jbc.M203222200 on July 26, 2002
J. Biol. Chem., Vol. 277, Issue 39, 36665-36670, September 27, 2002
A Major Functional Difference between the Mouse and Human
ARF Tumor Suppressor Proteins*
Renu
Wadhwa §,
Takashi
Sugihara¶,
Md. Kamrul
Hasan ,
Kazunari
Taira ,
Roger R.
Reddel**, and
Sunil C.
Kaul 
From the Gene Function Research Laboratory,
Research Center for Glycoscience, National Institute of Advanced
Industrial Science and Technology (AIST), 1-1-1 Higashi, Tsukuba,
Ibaraki 305-8566, Japan, the § Chugai Research Institute for
Medical Sciences, 153-2 Nagai, Niihari-mura, Ibaraki 300-4101, Japan,
the ¶ Department of Radiobiology, Institute for Environmental
Sciences, 1-7 Obuchi Ienomae Rokkasyo, Kamikita, Aomori, 039-3212, Japan, and the ** Children's Medical Research Institute, 214 Hawkesbury Road, Westmead, New South Wales 2145, Australia
Suppression of tumorigenesis is considerably more
stringent in the human than in the much shorter lived mouse species,
and the reasons for this difference are poorly understood. We
investigated functional differences in the control of the ARF
(alternative reading frame) protein
that acts upstream of p53 and is encoded along with
p16INK4a at a major tumor suppressor locus in both the
human and mouse genomes. The mouse and human ARF proteins are
substantially divergent at their carboxyl termini. We have shown that
the mouse ARF protein (p19ARF) interacts with Pex19p in the cell
cytoplasm leading to its nuclear exclusion and repression of its p53
activation function. The human ARF protein (p14ARF) is substantially
smaller than its mouse counterpart and is not subject to this
functional inactivation by Pex19p. In an identical cellular background,
ribozymes directed against Pex19p enhanced p19ARF- but not
p14ARF-activated p53 function. This is the first demonstration of a
functional difference between the mouse and human ARF proteins. In view
of the major role of ARF in tumor suppression, this distinction may
contribute to the different levels of tumor proneness of these species.
*
This work was supported in part by a Hougateki research
grant from the National Institute of Advanced Industrial Science and Technology (to S. C. K.) and by a carcinogenesis fellowship from the
Cancer Council of New South Wales (to R. R. R.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 81-298-61- 6713; Fax: 81-298-61-6692; E-mail: s-kaul@aist.go.jp.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
N. Widodo, C. C. Deocaris, K. Kaur, K. Hasan, T. Yaguchi, K. Yamasaki, T. Sugihara, T. Ishii, R. Wadhwa, and S. C. Kaul
Stress Chaperones, Mortalin, and Pex19p Mediate 5-Aza-2' Deoxycytidine-Induced Senescence of Cancer Cells by DNA Methylation-Independent Pathway
J. Gerontol. A Biol. Sci. Med. Sci.,
March 1, 2007;
62(3):
246 - 255.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|